CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) has received a consensus rating of “Moderate Buy” from the nineteen research firms covering the company, reports Marketbeat.com. One investment analyst has assigned a sell rating to the stock, six have given a hold rating and nine have given a buy rating to the company. The average 12-month price target from brokers who have updated their coverage of the stock over the past year is $112.33.
Several brokers have commented on CRSP. Oppenheimer lowered its target price on CRISPR Therapeutics to $122.00 from $150.00 and gave the stock a “Outperform” rating in a research report on Thursday, June 23. TheStreet downgraded CRISPR Therapeutics from a “c” rating to a “d” rating in a research note on Thursday, August 18. BMO Capital Markets assumed coverage of CRISPR Therapeutics in a research report on Thursday, June 16. They gave the company an Outperform rating and a target price of $98.00. Citigroup raised its target price on CRISPR Therapeutics to $83.00 from $53.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 2. Finally, Piper Sandler raised her price target on CRISPR Therapeutics to $121.00 from $115.00 and gave the company an overweight rating in a report Wednesday, June 22.
Insiders place their bets
In other news from CRISPR Therapeutics, CEO Samarth Kulkarni sold 25,000 shares of the company’s stock in a transaction on Wednesday, July 27. The shares sold at an average price of $75.91 for a total value of $1,897,750.00. Upon completion of the sale, the Chief Executive Officer now directly owns 290,279 shares of the Company, valued at $22,035,078.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC’s website. Insiders sold 75,000 shares of the company’s stock valued at $5,108,500 over the past three months. Insiders own 5.30% of the company’s shares.
Hedge funds bet on CRISPR therapeutics
A number of hedge funds have recently changed their holdings of CRSP. Northern Trust Corp increased its position in shares of CRISPR Therapeutics by 2.4% in the fourth quarter. Northern Trust Corp now owns 43,308 shares of the company’s stock valued at $3,282,000 after purchasing an additional 1,007 shares during the period. Citigroup Inc. increased its position in CRISPR Therapeutics stock by 8.0% during the fourth quarter. Citigroup Inc. now owns 30,788 shares of the company’s stock valued at $2,332,000 after purchasing an additional 2,275 shares during the period. Allianz Asset Management GmbH increased its position in shares of CRISPR Therapeutics by 2.6% in the fourth quarter. Allianz Asset Management GmbH now owns 43,137 shares of the company’s stock valued at $3,277,000 after purchasing an additional 1,075 shares during the period. Rockefeller Capital Management LP increased its position in CRISPR Therapeutics stock by 38.4% during the fourth quarter. Rockefeller Capital Management LP now owns 23,662 shares of the company’s stock valued at $1,792,000 after purchasing an additional 6,569 shares during the period. Finally, IHT Wealth Management LLC increased its position in shares of CRISPR Therapeutics by 12.7% during the fourth quarter. IHT Wealth Management LLC now owns 7,385 shares of the company’s stock valued at $560,000 after purchasing an additional 835 shares during the period. Hedge funds and other institutional investors own 70.56% of the company’s shares.
CRISPR Therapeutics stock performance
NASDAQ:CRSP opened at $63.16 on Friday. CRISPR Therapeutics has a 1-year low of $42.51 and a 1-year high of $120.24. The stock has a market cap of $4.93 billion, a price-to-earnings ratio of -7.67 and a beta of 1.97. The company has a 50-day moving average of $72.39 and a 200-day moving average of $65.52.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last reported its quarterly earnings data on Monday, August 8th. The company reported earnings per share of ($2.40) for the quarter, missing the consensus estimate of ($2.23) by ($0.17). CRISPR Therapeutics had negative net margin of 4,274.02% and negative return on equity of 27.40%. The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $2.20 million. In the same quarter last year, the company earned $9.44 per share. The company’s quarterly revenue declined 100.0% compared to the same quarter last year. On average, equity analysts are forecasting CRISPR Therapeutics to post year-to-date earnings per share of -9.26.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that enables precise, targeted changes to genomic DNA. CRISPR Therapeutics has developed a portfolio of therapeutic programs across a broad spectrum of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide readers with the fastest, most accurate reporting. This story was reviewed by the MarketBeat editorial team before publication. Please send questions or comments about this story to [email protected]
Hear this before you consider CRISPR Therapeutics.
MarketBeat tracks Wall Street’s best-in-class, top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes hold… and CRISPR Therapeutics wasn’t on the list.
While CRISPR Therapeutics is currently rated a “Moderate Buy” by analysts, top analysts believe these five stocks are better buys.
Check out the five stocks here